Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." ?g. }

• _4 value "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." provenance.
• _4 value "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." provenance.
• _4 value "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." provenance.
• _4 value "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." provenance.
• _4 value "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." provenance.
• _4 value "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." provenance.
• _4 value "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." provenance.
• _4 value "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." provenance.
• _4 value "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." provenance.
• _4 value "rodents or humans are treated with the b3 adrenergic agonist CL316,243 (25, 26). Since b3 adrenergic receptors are expressed almost exclusively in fat, effects of these agents would be expected to be initiated by alterations in fat. Treatment with CL316,243 results in enhanced sensitivity of both whole body glucose uptake and suppression of hepatic glucose production (25). Thus, increasing glucose uptake selectively in fat with b3 adrenergic receptor agonists may improve whole body glucose uptake, with the effects in fat indirectly resulting in increased insulin sensitivity in liver." provenance.